1-(4-氯-2-硝基苯)乙酮 | 23082-51-1

• 物质功能分类: 有机原料 - 酮类化合物
• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 1-(4-氯-2-硝基苯)乙酮
• 中文别名: 4'-氯-2'-硝基苯乙酮；4-氯-2-硝基苯乙酮
• 英文名称: 4'-chloro-2'-nitroacetophenone
• 英文别名: 1-(4-chloro-2-nitrophenyl)ethanone；2-Nitro-4-chlor-acetophenon
• CAS: 23082-51-1
• 化学式: C₈H₆ClNO₃
• 分子量: 199.594
• InChiKey: PUUYGMZERWRIDS-UHFFFAOYSA-N

物化性质

• 熔点：
  55-56℃
• 沸点：
  157°C/9mmHg(lit.)
• 密度：
  1.378

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  62.9
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2914700090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  室温且干燥

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 1-(4-Chloro-2-nitrophenyl)ethanone
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 1-(4-Chloro-2-nitrophenyl)ethanone
CAS number: 23082-51-1

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C8H6ClNO3
Molecular weight: 199.6

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  1-(4-氯-2-硝基苯)乙酮 在 sodium tetrahydroborate 、 1,10-菲罗啉 、 氧气 、 potassium carbonate 、 copper dichloride 、 silver(l) oxide 作用下， 以 甲醇 、 二甲基亚砜 为溶剂， 140.0 ℃ 、500.01 kPa 条件下， 反应 36.0h， 生成 2,5-二氯硝基苯
  参考文献：
  名称：

  芳基醇的C（芳基）-C键的脱羟基烷基卤化。

  摘要：

  我们在本文中报道了铜介导的芳醇的侧向脱羟基烷基化卤化。有效裂解芳基醇的C（芳基）–C键，以优异的收率提供相应的芳基氯化物，溴化物和碘化物。在反应过程中，芳醇既可以用作芳族亲电子基团，也可以用作自由基合成基团。

  DOI：

  10.1039/d0cc02306j
• 作为产物：
  描述：

  对氯苯乙酮 在 吡啶 、 盐酸 、 dipotassium peroxodisulfate 、 silver(I) nitrite 、 水 、 palladium diacetate 作用下， 以 甲醇 、 乙醚 、 1,2-二氯乙烷 为溶剂， 反应 72.0h， 生成 1-(4-氯-2-硝基苯)乙酮
  参考文献：
  名称：

  硝基化合物的特异合成通过钯催化氮给体定向族C ？H硝化

  摘要：

  的N-杂芳族化合物的硝化：钯催化的直接的第一个例子邻芳基C的-nitration  H键进行说明。一系列氮杂芳烃，例如2-芳基喹喔啉，吡啶，吡唑和O-甲基肟被硝化，具有出色的化学和区域选择性（参见方案； DCE = 1,2-二氯乙烷）。初步的机理研究支持在氧化条件下涉及钯（II / III）和/或钯（II / IV）催化循环的银介导的自由基机理。

  DOI：

  10.1002/chem.201002581

文献信息

• [EN] INHIBITORS OF KRAS G12C<br/>[FR] INHIBITEURS DE K-RAS G12C
  申请人：ARAXES PHARMA LLC

  公开号：WO2015054572A1

  公开（公告）日：2015-04-16

  Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have the following structure (I): or a pharmaceutically acceptable salt, tautomer, prodrug or stereoisomer thereof, wherein R1, R2a, R3a, R3b, R4a, R4b, G1, G2, L1, L2, m1, m2, A, B, W, X, Y, Z and E are as defined herein. Methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds and methods to modulate the activity of G12C mutant KRAS protein for treatment of disorders, such as cancer, are also provided.

  提供了作为G12C突变KRAS蛋白抑制剂活性的化合物。这些化合物具有以下结构（I）：或其药用可接受的盐、互变异构体、前药或立体异构体，其中R1、R2a、R3a、R3b、R4a、R4b、G1、G2、L1、L2、m1、m2、A、B、W、X、Y、Z和E如本文所定义。还提供了与制备和使用这些化合物相关的方法，包括含有这些化合物的药物组合物以及调节G12C突变KRAS蛋白活性以治疗癌症等疾病的方法。
• [EN] PIPERAZINE DERIVATIVES USEFUL FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS<br/>[FR] DERIVES DE PIPERAZINE CONVENANT POUR LE TRAITEMENT DE TROUBLES GASTRO-INTESTINAUX
  申请人：GLAXO GROUP LTD

  公开号：WO2006010629A1

  公开（公告）日：2006-02-02

  The invention provides compounds of formula (I) or pharmaceutically acceptable salts thereof, wherein Ra, Rb, Rc, Rd, Re, Rf and Y are as defined in the specification. The compounds are partial or full agonists at the growth hormone secretagogue (GHS) receptors . Pharmaceutical compositions comprising the compounds, methods of preparing the compounds, uses of the compounds and methods involving the compounds are also provided.

  这项发明提供了式（I）的化合物或其药用盐，其中Ra、Rb、Rc、Rd、Re、Rf和Y如规范中所定义。这些化合物是生长激素分泌素（GHS）受体的部分或全激动剂。还提供了包括这些化合物的药物组合物、制备这些化合物的方法、这些化合物的用途以及涉及这些化合物的方法。
• Base-Mediated [3 + 4]-Cycloaddition of Anthranils with Azaoxyallyl Cations: A New Approach to Multisubstituted Benzodiazepines
  作者：Juan Feng、Meng Zhou、Xuanzi Lin、An Lu、Xiaoyi Zhang、Ming Zhao

  DOI：10.1021/acs.orglett.9b02118

  日期：2019.8.16

  A new [3 + 4] cycloaddition of azaoxyallyl cations and anthranils has been achieved for rapid access to multisubstituted benzodiazepine derivatives. A variety of anthranils and α-halo hydroxamates were both effective substrates with simple operations under transition-metal-free conditions. The intriguing features of this method include its mild nature of the reaction conditions, high efficiency, broad

  为了快速获得多取代的苯并二氮杂衍生物，已经实现了新的[3 + 4]氮杂烯丙基阳离子和蒽基的环加成反应。多种蒽类和α-卤代异羟肟酸酯都是有效的底物，在无过渡金属的条件下操作简单。该方法的引人入胜的特征包括其反应条件温和的性质，高效率，广泛的底物范围和广泛的官能团相容性。
• Synthesis of thioethers, arenes and arylated benzoxazoles by transformation of the C(aryl)–C bond of aryl alcohols
  作者：Mingyang Liu、Zhanrong Zhang、Bingfeng Chen、Qinglei Meng、Pei Zhang、Jinliang Song、Buxing Han

  DOI：10.1039/d0sc01229g

  日期：——

  Transformation of aryl alcohols into high-value functionalized aromatic compounds by selective cleavage and functionalization of the C(aryl)–C(OH) bond is of crucial importance, but very challenging by far. Herein, for the first time, we report a novel and versatile strategy for activation and functionalization of C(aryl)–C(OH) bonds by the cooperation of oxygenation and decarboxylative functionalization

  通过对C（芳基）–C（OH）键的选择性裂解和官能化将芳基醇转化为高价值的官能化芳族化合物至关重要，但到目前为止仍极具挑战性。在此，我们首次报道了通过氧化和脱羧功能化的合作来激活和官能化C（芳基）–C（OH）键的新颖且通用的策略。在基于铜的催化系统中，通过裂解C（芳基）–C（OH）键，可以使用多种芳基醇底物作为芳基化试剂，并以优异的收率有效地转化为相应的硫醚，芳烃和芳基化苯并恶唑产品Ø 2作为氧化剂。这项研究为芳基醇的转化提供了一种新方法，并为从木质素等可再生原料生产高价官能化芳烃提供了新的机会，木质素在其键合中具有丰富的C（芳基）-C（OH）键。
• Dihydroquinone and dihydronaphthridine inhibitors of JNK
  申请人：Abbot Sarah C.

  公开号：US20080287458A1

  公开（公告）日：2008-11-20

  Compounds of formula I are effective modulators of JNK: wherein X is CR 11 or N; Y is —C(O)R 3 , 5-membered heteroaryl, or 5-membered heterocyclyl; Z is phenyl, cycloalkyl, heterocyclyl or heteroaryl, and is substituted with R 1 and R 2 ; R 1 and R 2 are each independently H, halo, CN, lower alkyl, or —Y 1 —Y 2 —Y 3 —R 8 , or R 1 and R 2 together form —O(CH 2 ) n O—, where n is 1 or 2; Y 1 is —O—, —C(O)—, —C(O)O—, —C(O)NR 9 —, —NR 9 C(O)—, —S—, —SO 2 —, or a bond; Y 2 is cycloalkylene, heterocycloalkylene, lower alkylene or a bond; Y 3 is —O—, —C(O)—, —C(O)O—, —C(O)NR 9 —, —NR 9 C(O)—, —SO 2 —, or a bond; R 8 is H, lower alkyl, lower alkoxy, cycloalkyl, heterocycloalkyl, or —NR 9 R 10 , wherein R 8 other than H is optionally substituted with lower alkyl, halo, —CF 3 , or —OH; R 9 and R 10 are each independently H or lower alkyl; R 3 is OH, lower alkyl, lower alkoxy, (lower alkoxy)-lower alkoxy, or —NR 9 R 10 ; R 4 is lower alkyl, phenyl, heterocyclyl, cycloalkyl, heterocycloalkyl, or heteroaryl, and is optionally substituted with lower alkyl, hydroxy, lower alkoxy, halo, nitro, amino, cyano, or halo-lower alkyl; R 5 and R 6 are each independently H, halo, cyano, lower alkyl, —CF 3 , lower alkoxy, —OCHF 2 , —NO 2 , or —NR 9 R 10 ; R 7 is H, F, Cl, methyl, or OH; R 11 is H, lower alkyl, lower cycloalkyl, or phenyl; or a pharmaceutically acceptable salt thereof.

  式I的化合物是JNK的有效调节剂： 其中 X为CR11或N； Y为—C(O)R3，5-成员杂芳基，或5-成员杂环烷基； Z为苯基，环烷基，杂环烷基或杂芳基，并且被R1和R2取代； R1和R2各自独立地为H，卤素，CN，较低烷基，或—Y1—Y2—Y3—R8，或R1和R2一起形成—O(CH2)nO—，其中n为1或2； Y1为—O—，—C(O)—，—C(O)O—，—C(O)NR9—，—NR9C(O)—，—S—，—SO2—，或键； Y2为环烷亚烷基，杂环烷亚烷基，较低烷基亚烷基或键； Y3为—O—，—C(O)—，—C(O)O—，—C(O)NR9—，—NR9C(O)—，—SO2—，或键； R8为H，较低烷基，较低烷氧基，环烷基，杂环烷基，或—NR9R10，其中R8除H外可选择地被较低烷基，卤素，—CF3，或—OH取代； R9和R10各自独立地为H或较低烷基； R3为OH，较低烷基，较低烷氧基，(较低烷氧基)-较低烷氧基，或—NR9R10； R4为较低烷基，苯基，杂环烷基，环烷基，杂环烷基，或杂芳基，并且可选择地被较低烷基，羟基，较低烷氧基，卤素，硝基，氨基，氰基，或卤素较低烷基取代； R5和R6各自独立地为H，卤素，氰基，较低烷基，—CF3，较低烷氧基，—OCHF2，—NO2，或—NR9R10； R7为H，F，Cl，甲基，或OH； R11为H，较低烷基，较低环烷基，或苯基； 或其药用可接受盐。